MetaCap

Compass Therapeutics (CMPX) vs Palisade Bio (PALI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Palisade Bio (PALI) has outperformed Compass Therapeutics (CMPX) over the past year, losing 60.6% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $123.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMPX-85.87%PALI-60.57%
+44%-25%-94%
Nov 21, 20251 yearNov 20, 2026
CMPX-80.22%PALI-99.95%
+97%-6%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMPX versus PALI key metrics
MetricCMPXPALI
Share price$0.6882$0.8399
Market cap$123.94M$150.74M
1-day change+1.43%-9.24%
YTD return-87.18%-64.26%
1-year return-85.87%-60.57%
5-year return-78.63%-99.95%
P/E ratio (TTM)—0.91
EPS (TTM)$-0.46$0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-66.49M$-16.78M
52-week high$6.88$2.86
52-week low$0.57$0.8381
Distance from 52-week high-90.00%-70.63%
Analyst consensusbuystrong_buy
Avg. price target upside+664.31%+935.84%
Average volume3.88M3.19M
Shares outstanding180.09M179.28M
Employees3914
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PALI has outperformed CMPX by 25.3 percentage points over the past year.

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About Palisade Bio

PALI stock →

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

CMPX vs PALI FAQ

Which is bigger, Compass Therapeutics or Palisade Bio?

Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $123.94M for Compass Therapeutics (CMPX).

Which stock has performed better over the past year, CMPX or PALI?

PALI returned -60.57% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Compass Therapeutics and Palisade Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons